Yun-Long Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yun-Long Zhang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Hui-Hua Li
Institute of Cardiovascular Diseases First Affiliated Hospital of Dalian Medical University Dalian China
6 shared publications Xiao Han
Central Hospital of Dalian University of Technology
6 shared publicationsJia-Kang He
Department of Cardiology, First Affiliated Hospital of Dalian Medical University, No.193, Lianhe Road, Xigang District, Dalian 116011, China
4 shared publications- Xiao Han
Institute of Cardio-Cerebrovascular Medicine, Central Hospital of Dalian University of Technology, Dalian, China
4 shared publications - Xiao-Hong Yu
Department of Cardiology First Affiliated Hospital of Dalian Medical University Dalian China
4 shared publications - Bo Zhang
Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Wiley in Advanced Science
- p. e77663
Interleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis
Sepsis remains a global health crisis with high mortality, due to a paucity of reliable diagnostic markers for accurate risk stratification and precision management. Interleukin‐39 (IL‐39), a novel immunomodulatory cytokine, plays an important role in regulating the pathophysiology of immunity, metabolism, and et al. Here, we observed significantly elevated serum IL‐39 levels in septic patients at admission compared with non‐sepsis ICU patients and healthy controls across two independent cohorts. Furthermore, circulating IL‐39 concentrations could predict 28‐days survival in patients with sepsis. Single‐cell sequencing demonstrated that elevated IL‐39 was derived from macrophages during sepsis. Meanwhile, supplementation of IL‐39, via either recombinant protein (rmIL‐39) administration or macrophage‐specific AAV‐mediated overexpression, profoundly aggravates multiple organ dysfunction and damage in septic mice. Consistently, macrophage IL‐39 deficiency, via either macrophage‐conditional knockout or macrophage‐specific AAV‐mediated silence, protects against sepsis. Mechanistically, IL‐39 engages GP130 to trigger MAPK/P38 signaling, driving pro‐inflammatory cytokine production. Consequently, macrophage‐specific GP130 deletion abrogates IL‐39‐induced sepsis aggravation. Finally, pharmaceutical inhibition of IL‐39 with neutralizing antibodies can protect against sepsis. Together, these results highlight the dual clinical utility of IL‐39, as both a robust biomarker with independent prognostic value for sepsis patient stratification and a promising therapeutic strategy for sepsis.
- 10 September 2026
- Published by Wiley in Advanced Science
- p. e77663
Open AccessInterleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis
Sepsis remains a global health crisis with high mortality, due to a paucity of reliable diagnostic markers for accurate risk stratification and precision management. Interleukin‐39 (IL‐39), a novel immunomodulatory cytokine, plays an important role in regulating the pathophysiology of immunity, metabolism, and et al. Here, we observed significantly elevated serum IL‐39 levels in septic patients at admission compared with non‐sepsis ICU patients and healthy controls across two independent cohorts. Furthermore, circulating IL‐39 concentrations could predict 28‐days survival in patients with sepsis. Single‐cell sequencing demonstrated that elevated IL‐39 was derived from macrophages during sepsis. Meanwhile, supplementation of IL‐39, via either recombinant protein (rmIL‐39) administration or macrophage‐specific AAV‐mediated overexpression, profoundly aggravates multiple organ dysfunction and damage in septic mice. Consistently, macrophage IL‐39 deficiency, via either macrophage‐conditional knockout or macrophage‐specific AAV‐mediated silence, protects against sepsis. Mechanistically, IL‐39 engages GP130 to trigger MAPK/P38 signaling, driving pro‐inflammatory cytokine production. Consequently, macrophage‐specific GP130 deletion abrogates IL‐39‐induced sepsis aggravation. Finally, pharmaceutical inhibition of IL‐39 with neutralizing antibodies can protect against sepsis. Together, these results highlight the dual clinical utility of IL‐39, as both a robust biomarker with independent prognostic value for sepsis patient stratification and a promising therapeutic strategy for sepsis.
- Open Access
- 21 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6464
The Application of Injectable Hydrogels in Myocardial Infarction Repair: Material Design, Biological Functions and Clinical Translation
Myocardial infarction remains a major clinical challenge because ischemic injury triggers inflammation, oxidative stress, cardiomyocyte loss, impaired vascularization, and adverse ventricular remodeling. Injectable hydrogels offer a minimally invasive and versatile strategy for post-infarction cardiac repair by providing structural support, localized bioactive delivery, and dynamic modulation of the injured myocardial microenvironment. This review highlights pathology-informed design principles for injectable hydrogels, including shear-thinning injectability, in situ gelation, tissue adhesion, modulus matching, fatigue resistance, biodegradability, and controlled bioactivity. We further discuss hydrogel-based strategies for immunomodulation, angiogenesis, fibrosis attenuation, extracellular matrix remodeling, and myocardial regeneration. Finally, translational progress and key challenges involving biosafety, scalable manufacturing, standardization and long-term efficacy are examined. This review provides a concise framework for developing next-generation injectable hydrogels for myocardial infarction repair and clinical translation.
- 21 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6464
Open AccessThe Application of Injectable Hydrogels in Myocardial Infarction Repair: Material Design, Biological Functions and Clinical Translation
Myocardial infarction remains a major clinical challenge because ischemic injury triggers inflammation, oxidative stress, cardiomyocyte loss, impaired vascularization, and adverse ventricular remodeling. Injectable hydrogels offer a minimally invasive and versatile strategy for post-infarction cardiac repair by providing structural support, localized bioactive delivery, and dynamic modulation of the injured myocardial microenvironment. This review highlights pathology-informed design principles for injectable hydrogels, including shear-thinning injectability, in situ gelation, tissue adhesion, modulus matching, fatigue resistance, biodegradability, and controlled bioactivity. We further discuss hydrogel-based strategies for immunomodulation, angiogenesis, fibrosis attenuation, extracellular matrix remodeling, and myocardial regeneration. Finally, translational progress and key challenges involving biosafety, scalable manufacturing, standardization and long-term efficacy are examined. This review provides a concise framework for developing next-generation injectable hydrogels for myocardial infarction repair and clinical translation.
- Open Access
- 5 May 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (6) , 168285
Temporal gene expression profiling reveals the protective mechanism of APIP in atrial fibrillation following myocardial infarction
- 5 May 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (6) , 168285
Open AccessTemporal gene expression profiling reveals the protective mechanism of APIP in atrial fibrillation following myocardial infarction
- Open Access
- 21 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117920
MnTBAP attenuates pulmonary hypertension-induced right ventricular dysfunction and remodeling by modulating the CaMKIIδ-SERCA2a signaling pathway
- 21 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117920
Open AccessMnTBAP attenuates pulmonary hypertension-induced right ventricular dysfunction and remodeling by modulating the CaMKIIδ-SERCA2a signaling pathway
- Open Access
- 14 August 2025
- Published by Portland Press Ltd. in Clinical Science
- Vol. 139 (17) , 923-940
FAP deficiency attenuates T2DM-associated HFpEF by suppressing the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway
Heart failure with preserved ejection fraction (HFpEF) represents the initial phase of cardiac dysfunction associated with type 2 diabetes mellitus (T2DM). To date, the pathophysiological mechanisms underlying T2DM-induced HFpEF are complex and elusive. Fibroblast activation protein (FAP) is a prolyl-specific serine protease that its inhibition or vaccination has been shown to enhance cardiac repair following myocardial infarction (MI). However, the role and underlying molecular mechanisms by which abnormal FAP activity promotes the development of T2DM-induced HFpEF remain to be elucidated. In this study, the plasma activity and level of FAP were significantly higher in the T2DM with HFpEF group compared to the healthy control group. Moreover, plasma FAP activity and level were positively correlated with the likelihood of T2DM with HFpEF. To investigate the mechanistic involvement of FAP in the development of T2DM-associated HFpEF, a chronic T2DM mouse model was established. The results revealed that FAP KO significantly improved BNP level and E/A ratios compared to the WT T2DM group. Additionally, FAP KO and FAP inhibitor Talabostat alleviated myocardial inflammation, fibrosis, cardiomyocyte apoptosis, oxidative stress and energy metabolism dysfunction. Mechanistically, abnormal increase FAP triggered the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway, leading to the aforementioned pathological changes in T2DM-induced HFpEF. In contrast, FAP KO suppressed the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway and attenuated these pathological changes. Overall, these findings suggest that FAP may serve as a critical therapeutic target for T2DM-induced HFpEF.
- 14 August 2025
- Published by Portland Press Ltd. in Clinical Science
- Vol. 139 (17) , 923-940
Open AccessFAP deficiency attenuates T2DM-associated HFpEF by suppressing the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway
Heart failure with preserved ejection fraction (HFpEF) represents the initial phase of cardiac dysfunction associated with type 2 diabetes mellitus (T2DM). To date, the pathophysiological mechanisms underlying T2DM-induced HFpEF are complex and elusive. Fibroblast activation protein (FAP) is a prolyl-specific serine protease that its inhibition or vaccination has been shown to enhance cardiac repair following myocardial infarction (MI). However, the role and underlying molecular mechanisms by which abnormal FAP activity promotes the development of T2DM-induced HFpEF remain to be elucidated. In this study, the plasma activity and level of FAP were significantly higher in the T2DM with HFpEF group compared to the healthy control group. Moreover, plasma FAP activity and level were positively correlated with the likelihood of T2DM with HFpEF. To investigate the mechanistic involvement of FAP in the development of T2DM-associated HFpEF, a chronic T2DM mouse model was established. The results revealed that FAP KO significantly improved BNP level and E/A ratios compared to the WT T2DM group. Additionally, FAP KO and FAP inhibitor Talabostat alleviated myocardial inflammation, fibrosis, cardiomyocyte apoptosis, oxidative stress and energy metabolism dysfunction. Mechanistically, abnormal increase FAP triggered the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway, leading to the aforementioned pathological changes in T2DM-induced HFpEF. In contrast, FAP KO suppressed the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway and attenuated these pathological changes. Overall, these findings suggest that FAP may serve as a critical therapeutic target for T2DM-induced HFpEF.
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e038142
CD11b Blockade Ameliorates Myocardial Ischemia/Reperfusion Injury by Reducing Neutrophil and Monocyte Infiltration
Background: Myocardial ischemia/reperfusion (I/R) injury is a leading cause of myocardial dysfunction and is associated with inflammation, apoptosis, and fibrosis. The integrin subunit ITGAM (also known as CD11b) mainly mediates leukocyte infiltration in the inflammatory process. However, the importance of CD11b in the development of myocardial I/R injury is unclear. The goal of this study is to investigate the role of CD11b + immune cells, particularly neutrophils and macrophages, in mediating myocardial I/R injury and to evaluate the therapeutic potential of CD11b inhibition. Methods: Wild‐type mice were administered an anti‐CD11b neutralizing antibody before myocardial I/R surgery. Echocardiography and histological staining were used to evaluate cardiac function and injury, respectively. Inflammatory cells were analyzed by flow cytometry in mice and patients with myocardial infarction who underwent percutaneous coronary intervention. Activated fibroblasts from patients with myocardial infarction were detected by positron emission tomography/computed tomography with a [(18)F]‐labeled fibroblast activation protein inhibitor. Results: Our results indicated that CD11b expression and the number of CD45 + CD11b + bone marrow mononuclear cells were dramatically increased in the heart tissues of I/R‐treated mice. Moreover, compared with immunoglobulin G treatment, the pharmacological inhibition of CD11b in mice greatly alleviated cardiac dysfunction, infarct size, myocyte apoptosis, CD11b + neutrophils and macrophage infiltration, cardiac fibrosis and fibroblast activation, accompanied by the inhibition of multiple signaling pathways (Bax, caspase‐3, nuclear factor‐κB, and transforming growth factor‐β/Smad2/3) 3 days after I/R surgery. In addition, the numbers of CD15 + CD11b + neutrophils and CD14 + CD11b + monocytes and the levels of inflammatory cytokines (intercellular adhesion molecule ‐1, vascular adhesion molecule ‐1, interleukin‐1β, and interleukin‐6) as well as the levels of fibroblast activation protein inhibitor in patients with myocardial infarction were also significantly greater than those in normal controls. Conclusions: Our data demonstrate that CD11b plays an important role in promoting myocardial I/R injury through multiple signaling pathways and that targeting CD11b may represent a promising option for treating heart I/R injury.
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e038142
Open AccessCD11b Blockade Ameliorates Myocardial Ischemia/Reperfusion Injury by Reducing Neutrophil and Monocyte Infiltration
Background: Myocardial ischemia/reperfusion (I/R) injury is a leading cause of myocardial dysfunction and is associated with inflammation, apoptosis, and fibrosis. The integrin subunit ITGAM (also known as CD11b) mainly mediates leukocyte infiltration in the inflammatory process. However, the importance of CD11b in the development of myocardial I/R injury is unclear. The goal of this study is to investigate the role of CD11b + immune cells, particularly neutrophils and macrophages, in mediating myocardial I/R injury and to evaluate the therapeutic potential of CD11b inhibition. Methods: Wild‐type mice were administered an anti‐CD11b neutralizing antibody before myocardial I/R surgery. Echocardiography and histological staining were used to evaluate cardiac function and injury, respectively. Inflammatory cells were analyzed by flow cytometry in mice and patients with myocardial infarction who underwent percutaneous coronary intervention. Activated fibroblasts from patients with myocardial infarction were detected by positron emission tomography/computed tomography with a [(18)F]‐labeled fibroblast activation protein inhibitor. Results: Our results indicated that CD11b expression and the number of CD45 + CD11b + bone marrow mononuclear cells were dramatically increased in the heart tissues of I/R‐treated mice. Moreover, compared with immunoglobulin G treatment, the pharmacological inhibition of CD11b in mice greatly alleviated cardiac dysfunction, infarct size, myocyte apoptosis, CD11b + neutrophils and macrophage infiltration, cardiac fibrosis and fibroblast activation, accompanied by the inhibition of multiple signaling pathways (Bax, caspase‐3, nuclear factor‐κB, and transforming growth factor‐β/Smad2/3) 3 days after I/R surgery. In addition, the numbers of CD15 + CD11b + neutrophils and CD14 + CD11b + monocytes and the levels of inflammatory cytokines (intercellular adhesion molecule ‐1, vascular adhesion molecule ‐1, interleukin‐1β, and interleukin‐6) as well as the levels of fibroblast activation protein inhibitor in patients with myocardial infarction were also significantly greater than those in normal controls. Conclusions: Our data demonstrate that CD11b plays an important role in promoting myocardial I/R injury through multiple signaling pathways and that targeting CD11b may represent a promising option for treating heart I/R injury.
- Open Access
- 24 December 2024
- Published by Springer Nature in Hypertension Research
- Vol. 48 (3) , 1054-1067
4-Hydroxychalcone attenuates AngII-induced cardiac remodeling and dysfunction via regulating PI3K/AKT pathway
Cardiac remodeling encompasses structural alterations such as hypertrophy, fibrosis, and dilatation, alongside numerous cellular and molecular functional aberrations, constituting a pivotal process in the advancement of heart failure (HF). 4-Hydroxychalcone (4-HCH) is a class of naturally occurring compounds with variable phenolic structures, and has demonstrated the preventive efficacy in hyperaldosteronism, inflammation and renal injury. However, the role of 4-HCH in the regulation of cardiac remodeling remains uncertain. A cardiac remodeling model was established in male C57BL/6 J mice via subcutaneous Ang II (1000 or 300 ng/kg/min) for 2 weeks. Mice were treated with 4-HCH (20 or 40 mg/kg/day) or vehicle control. Systolic blood pressure (SBP) was measured using a tail-cuff method, and echocardiography assessed cardiac function. Histopathological staining evaluated cardiomyocyte hypertrophy, fibrosis, inflammation, and superoxide production. Network pharmacology analysis identified potential core targets and pathways mediating the effects of 4-HCH. Expression of inflammatory cytokines and proteins related to hypertrophy, fibrosis, inflammation, and oxidative stress was assessed by quantitative real-time PCR (qPCR) and Western blotting. Our results indicated that 4-HCH significantly ameliorated Ang II-induced hypertension, cardiomyocyte hypertrophy, fibroblast activation, fibrosis, inflammation, superoxide production, and cardiac function. Network pharmacology analysis identified the PI3K-AKT pathway as a crucial mechanism underlying the effects of 4-HCH, with experimental verification demonstrating that it inhibits cardiac remodeling by downregulating this pathway and its downstream effectors, including mTOR/ERK, TGF-β/Smad2/3, NF-κB, and NOX1 independent of its blood pressure-lowering effects. These results reveal for the first time that 4-HCH alleviates cardiac remodeling, emphasizing its potential as a therapeutic agent for HF.
- 24 December 2024
- Published by Springer Nature in Hypertension Research
- Vol. 48 (3) , 1054-1067
Open Access4-Hydroxychalcone attenuates AngII-induced cardiac remodeling and dysfunction via regulating PI3K/AKT pathway
Cardiac remodeling encompasses structural alterations such as hypertrophy, fibrosis, and dilatation, alongside numerous cellular and molecular functional aberrations, constituting a pivotal process in the advancement of heart failure (HF). 4-Hydroxychalcone (4-HCH) is a class of naturally occurring compounds with variable phenolic structures, and has demonstrated the preventive efficacy in hyperaldosteronism, inflammation and renal injury. However, the role of 4-HCH in the regulation of cardiac remodeling remains uncertain. A cardiac remodeling model was established in male C57BL/6 J mice via subcutaneous Ang II (1000 or 300 ng/kg/min) for 2 weeks. Mice were treated with 4-HCH (20 or 40 mg/kg/day) or vehicle control. Systolic blood pressure (SBP) was measured using a tail-cuff method, and echocardiography assessed cardiac function. Histopathological staining evaluated cardiomyocyte hypertrophy, fibrosis, inflammation, and superoxide production. Network pharmacology analysis identified potential core targets and pathways mediating the effects of 4-HCH. Expression of inflammatory cytokines and proteins related to hypertrophy, fibrosis, inflammation, and oxidative stress was assessed by quantitative real-time PCR (qPCR) and Western blotting. Our results indicated that 4-HCH significantly ameliorated Ang II-induced hypertension, cardiomyocyte hypertrophy, fibroblast activation, fibrosis, inflammation, superoxide production, and cardiac function. Network pharmacology analysis identified the PI3K-AKT pathway as a crucial mechanism underlying the effects of 4-HCH, with experimental verification demonstrating that it inhibits cardiac remodeling by downregulating this pathway and its downstream effectors, including mTOR/ERK, TGF-β/Smad2/3, NF-κB, and NOX1 independent of its blood pressure-lowering effects. These results reveal for the first time that 4-HCH alleviates cardiac remodeling, emphasizing its potential as a therapeutic agent for HF.
- Open Access
- 5 November 2024
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (1) , 133-145
β-Hydroxybutyrate and Citrate Synthase as Potential Diagnostic Biomarkers in Aging-Related Atrial Fibrillation
The incidence of atrial fibrillation (AF) increases with age; however, the precise mechanisms by which aging elevates AF risk and the effective biomarkers for managing AF in elderly patients remain unclear. We analyzed plasma samples from 100 elderly AF patients, 100 young and 100 elderly patients without atrial fibrillation (NAF), along with left atrial tissues obtained from both AF and NAF patients following valve replacement. Our findings indicate reduced levels of β-OHB and citrate synthase (CS) activity in elderly AF patients compared to their NAF counterparts. Statistical analysis revealed a protective association between β-OHB and CS activity concerning the occurrence of elderly AF. Furthermore, atrial tissues from elderly AF patients exhibited mitochondrial dysfunction, structural remodeling, and low-voltage areas. These results suggest that dysregulation of β-OHB levels and CS activity may contribute to aging-related AF by affecting mitochondrial function and atrial remodeling, highlighting their potential as diagnostic biomarkers for this condition. Graphical Abstract
- 5 November 2024
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (1) , 133-145
Open Accessβ-Hydroxybutyrate and Citrate Synthase as Potential Diagnostic Biomarkers in Aging-Related Atrial Fibrillation
The incidence of atrial fibrillation (AF) increases with age; however, the precise mechanisms by which aging elevates AF risk and the effective biomarkers for managing AF in elderly patients remain unclear. We analyzed plasma samples from 100 elderly AF patients, 100 young and 100 elderly patients without atrial fibrillation (NAF), along with left atrial tissues obtained from both AF and NAF patients following valve replacement. Our findings indicate reduced levels of β-OHB and citrate synthase (CS) activity in elderly AF patients compared to their NAF counterparts. Statistical analysis revealed a protective association between β-OHB and CS activity concerning the occurrence of elderly AF. Furthermore, atrial tissues from elderly AF patients exhibited mitochondrial dysfunction, structural remodeling, and low-voltage areas. These results suggest that dysregulation of β-OHB levels and CS activity may contribute to aging-related AF by affecting mitochondrial function and atrial remodeling, highlighting their potential as diagnostic biomarkers for this condition. Graphical Abstract
- Open Access
- 24 August 2023
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 82 (5) , 375-388
Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate–activated Citrate Synthase
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, accounting for 50% of all heart failure patients, and is associated with significant mortality. Sodium–glucose cotransporter subtype inhibitor (SGLT2i) is recommended in the AHA and ESC guidelines for the treatment of HFpEF, but the mechanism of SGLT2i to prevent and treat cardiac remodeling and dysfunction is currently unknown, hindering the understanding of the pathophysiology of HFpEF and the development of novel therapeutics. HFpEF model was induced by a high-fat diet (60% calories from lard) + N[w]-nitro-l-arginine methyl ester (l-NAME—0.5 g/L) (2 Hit) in male Sprague Dawley rats to effectively recapture the myriad phenotype of HFpEF. This study's results showed that administration of dapagliflozin (DAPA, SGLT2 inhibitor) significantly limited the 2-Hit–induced cardiomyocyte hypertrophy, apoptosis, inflammation, oxidative stress, and fibrosis. It also improved cardiac diastolic and systolic dysfunction in a late-stage progression of HFpEF. Mechanistically, DAPA influences energy metabolism associated with fatty acid intake and mitochondrial dysfunction in HFpEF by increasing β-hydroxybutyric acid (β-OHB) levels, directing the activation of citrate synthase, reducing acetyl coenzyme A (acetyl-CoA) pools, modulating adenosine 5′-triphosphate production, and increasing the expression of mitochondrial oxidative phosphorylation system complexes I-V. In addition, following clinical DAPA therapy, the blood levels of β-OHB and citrate synthase increased and the levels of acetyl-CoA in the blood of HFpEF patients decreased. SGLT2i plays a beneficial role in the prevention and treatment of cardiac remodeling and dysfunction in HFpEF model by attenuating cardiometabolic dysregulation.
- 24 August 2023
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 82 (5) , 375-388
Open AccessDapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate–activated Citrate Synthase
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, accounting for 50% of all heart failure patients, and is associated with significant mortality. Sodium–glucose cotransporter subtype inhibitor (SGLT2i) is recommended in the AHA and ESC guidelines for the treatment of HFpEF, but the mechanism of SGLT2i to prevent and treat cardiac remodeling and dysfunction is currently unknown, hindering the understanding of the pathophysiology of HFpEF and the development of novel therapeutics. HFpEF model was induced by a high-fat diet (60% calories from lard) + N[w]-nitro-l-arginine methyl ester (l-NAME—0.5 g/L) (2 Hit) in male Sprague Dawley rats to effectively recapture the myriad phenotype of HFpEF. This study's results showed that administration of dapagliflozin (DAPA, SGLT2 inhibitor) significantly limited the 2-Hit–induced cardiomyocyte hypertrophy, apoptosis, inflammation, oxidative stress, and fibrosis. It also improved cardiac diastolic and systolic dysfunction in a late-stage progression of HFpEF. Mechanistically, DAPA influences energy metabolism associated with fatty acid intake and mitochondrial dysfunction in HFpEF by increasing β-hydroxybutyric acid (β-OHB) levels, directing the activation of citrate synthase, reducing acetyl coenzyme A (acetyl-CoA) pools, modulating adenosine 5′-triphosphate production, and increasing the expression of mitochondrial oxidative phosphorylation system complexes I-V. In addition, following clinical DAPA therapy, the blood levels of β-OHB and citrate synthase increased and the levels of acetyl-CoA in the blood of HFpEF patients decreased. SGLT2i plays a beneficial role in the prevention and treatment of cardiac remodeling and dysfunction in HFpEF model by attenuating cardiometabolic dysregulation.
- Open Access
- 10 January 2022
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 40 (4) , 765-775
Time series proteome profile analysis reveals a protective role of citrate synthase in angiotensin II-induced atrial fibrillation
Background: Angiotensin (Ang) II and elevated blood pressure are considered to be the main risk factors for atrial fibrillation. However, the proteome profiles and key mediators/signaling pathways involved in the development of Ang II-induced atrial fibrillation remain unclear. Methods: Male wild-type C57BL/6 mice (10-week old) were infused with Ang II (2000 ng/kg per min) for 1, 2, or 3 weeks, respectively. Time series proteome profiling of atrial tissues was performed using isobaric tags for relative and absolute quantitation and liquid chromatography coupled with tandem mass spectrometry. Results: We identified a total of 1566 differentially expressed proteins (DEPs) in the atrial tissues at weeks 1, 2, and 3 after Ang II infusion. These DEPs were predominantly involved in mitochondrial oxidation-reduction and tricarboxylic acid cycle in Ang II-infused atria. Moreover, coexpression network analysis revealed that citrate synthase, a rate-limiting enzyme in the tricarboxylic acid cycle, was localized at the center of the mitochondrial oxidation-reduction process, and its expression was significantly downreguated in Ang II-infused atria at different time points. Cardiomyocyte-specific overexpresion of citrate synthase markedly reduced atrial fibrillation susceptibility and atrial remodeling in mice. These beneficial effects were associated with increased ATP production and mitochondrial oxidative phosphorylation system complexes I–V expression and inhibition of oxidative stress. Conclusion: The current study defines the dynamic changes of the DEPs involved in Ang II-induced atrial fibrillation, and identifies that citrate synthase plays a protective role in regulating atrial fibrillation development, and increased citrate synthase expression may represent a potential therapeutic option for atrial fibrillation treatment.
- 10 January 2022
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 40 (4) , 765-775
Open AccessTime series proteome profile analysis reveals a protective role of citrate synthase in angiotensin II-induced atrial fibrillation
Background: Angiotensin (Ang) II and elevated blood pressure are considered to be the main risk factors for atrial fibrillation. However, the proteome profiles and key mediators/signaling pathways involved in the development of Ang II-induced atrial fibrillation remain unclear. Methods: Male wild-type C57BL/6 mice (10-week old) were infused with Ang II (2000 ng/kg per min) for 1, 2, or 3 weeks, respectively. Time series proteome profiling of atrial tissues was performed using isobaric tags for relative and absolute quantitation and liquid chromatography coupled with tandem mass spectrometry. Results: We identified a total of 1566 differentially expressed proteins (DEPs) in the atrial tissues at weeks 1, 2, and 3 after Ang II infusion. These DEPs were predominantly involved in mitochondrial oxidation-reduction and tricarboxylic acid cycle in Ang II-infused atria. Moreover, coexpression network analysis revealed that citrate synthase, a rate-limiting enzyme in the tricarboxylic acid cycle, was localized at the center of the mitochondrial oxidation-reduction process, and its expression was significantly downreguated in Ang II-infused atria at different time points. Cardiomyocyte-specific overexpresion of citrate synthase markedly reduced atrial fibrillation susceptibility and atrial remodeling in mice. These beneficial effects were associated with increased ATP production and mitochondrial oxidative phosphorylation system complexes I–V expression and inhibition of oxidative stress. Conclusion: The current study defines the dynamic changes of the DEPs involved in Ang II-induced atrial fibrillation, and identifies that citrate synthase plays a protective role in regulating atrial fibrillation development, and increased citrate synthase expression may represent a potential therapeutic option for atrial fibrillation treatment.